Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act, 31622-31624 [2012-12878]
Download as PDF
31622
Federal Register / Vol. 77, No. 103 / Tuesday, May 29, 2012 / Notices
security measures are applicable. In
planning your arrival to the CMS
facility, we recommend allowing
additional time to clear security.
Attendees should arrive between 8:15
a.m. and 8:30 a.m., in order to be
prompt for the 9:00 a.m. meeting.
Individuals who are not registered in
advance will not be permitted to enter
the building and will be unable to
attend the meeting. The public may not
enter the building earlier than 8:15 a.m.
(45 minutes before the convening of the
meeting).
Security measures include the
following:
• Presentation of government-issued
photographic identification to the
Federal Protective Service or Guard
Service personnel. Persons without
proper identification may be denied
access to the building.
• Interior and exterior inspection of
vehicles (this includes engine and trunk
inspection) at the entrance to the
grounds. Parking permits and
instructions will be issued after the
vehicle inspection.
• Passing through a metal detector
and inspection of items brought into the
building. We note that all items brought
to CMS, whether personal or for the
purpose of demonstration or to support
a demonstration, are subject to
inspection. We cannot assume
responsibility for coordinating the
receipt, transfer, transport, storage, setup, safety, or timely arrival of any
personal belongings or items used for
demonstration or to support a
demonstration.
(Catalog of Federal Domestic Assistance
Program No. 93.773, Medicare—Hospital
Insurance; and Program No. 93.774,
Medicare—Supplementary Medical
Insurance Program)
Dated: May 22, 2012.
Marilyn Tavenner,
Acting Administrator, Centers for Medicare
& Medicaid Services.
[FR Doc. 2012–12982 Filed 5–25–12; 8:45 am]
srobinson on DSK4SPTVN1PROD with NOTICES
16:12 May 25, 2012
Food and Drug Administration
[Docket No. FDA–2012–N–0274]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Adverse Event
Reporting and Recordkeeping for
Dietary Supplements as Required by
the Dietary Supplement and
Nonprescription Drug Consumer
Protection Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by June 28,
2012.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0428. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400T, Rockville, MD 20850, 301–796–
5733, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUMMARY:
Adverse Event Reporting and
Recordkeeping for Dietary Supplements
as Required by the Dietary Supplement
and Nonprescription Drug Consumer
Protection Act—21 U.S.C. 379aa–1(b)(1)
(OMB Control Number 0910–0635)—
Extension
The Dietary Supplement and
Nonprescription Drug Consumer
Protection Act (DSNDCPA) (Pub. L.
109–462, 120 Stat. 3469) amends the
Federal Food, Drug, and Cosmetic Act
(the FD&C Act) with respect to serious
BILLING CODE 4120–01–P
VerDate Mar<15>2010
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Jkt 226001
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
adverse event reporting and
recordkeeping for dietary supplements
and nonprescription drugs marketed
without an approved application.
Section 761(b)(1) of the FD&C Act (21
U.S.C. 379aa–1(b)(1)) requires the
manufacturer, packer, or distributor
whose name (under section 403(e)(1) of
the FD&C Act (21 U.S.C. 343(e)(1)))
appears on the label of a dietary
supplement marketed in the United
States to submit to FDA all serious
adverse event reports associated with
the use of a dietary supplement,
accompanied by a copy of the product
label. The manufacturer, packer, or
distributor of a dietary supplement is
required by the DSNDCPA to use the
MedWatch form (FDA 3500A) when
submitting a serious adverse event
report to FDA. In addition, under
section 761(c)(2) of the FD&C Act, the
submitter of the serious adverse event
report (referred to in the statute as the
‘‘responsible person’’) is required to
submit to FDA a followup report of any
related new medical information the
responsible person receives within 1
year of the initial report.
Section 761(e)(1) of the FD&C Act (21
U.S.C. 379aa–1(e)(1)) requires that
responsible persons maintain records
related to the dietary supplement
adverse event reports they receive,
whether or not the adverse event is
serious. Under the statute, the records
must be retained for a period of 6 years.
As required by section 3(d)(3) of the
DSNDCPA, FDA issued guidance to
describe the minimum data elements for
serious adverse event reports for dietary
supplements. In the Federal Register of
July 14, 2009 (74 FR 34024), FDA
announced the availability of guidance
entitled ‘‘Guidance for Industry:
Questions and Answers Regarding
Adverse Event Reporting and
Recordkeeping for Dietary Supplements
as Required by the Dietary Supplement
and Nonprescription Drug Consumer
Protection Act.’’ The guidance discusses
how, when, and where to submit serious
adverse event reports for dietary
supplements and followup reports. The
guidance also provides FDA’s
recommendation on records
maintenance and access for serious and
non-serious adverse event reports and
related documents.
The guidance recommends that the
responsible person document the
attempts to obtain the minimum data
elements for a serious adverse event
report. Along with these records, the
guidance recommends that the
responsible person keep the following
other records: (1) Communications
between the responsible person and the
initial reporter of the adverse event and
E:\FR\FM\29MYN1.SGM
29MYN1
31623
Federal Register / Vol. 77, No. 103 / Tuesday, May 29, 2012 / Notices
between the responsible person and any
other person(s) who provided
information about the adverse event, (2)
the responsible person’s serious adverse
event report to FDA with attachments,
(3) any new information about the
adverse event received by the
responsible person, and (4) any reports
to FDA of new information related to
the serious adverse event report.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 U.S.C. Section
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total hours
21 U.S.C. 379aa–1(b)(1)—Serious adverse event reports
for dietary supplements ....................................................
21 U.S.C. 379aa–1(c)(2)—Followup reports of new medical information .................................................................
480
17
8,160
2
16,320
120
17
2,040
1
2,040
Total ..............................................................................
........................
........................
........................
........................
18,360
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
This estimate is based on FDA’s
experience with similar adverse event
reporting programs and the number of
serious adverse event reports and
followup reports received in the past 2
years. All dietary supplement
manufacturers, packers, or distributors
are subject to serious adverse event
mandatory reporting. In 2007, we
estimated in the final rule entitled
‘‘Current Good Manufacturing Practice
in Manufacturing, Packaging, Labeling,
or Holding Operations for Dietary
Supplements’’ (72 FR 34752, June 25,
2007) that there were 1,460 such firms.
FDA estimates that, in 2012, there are
approximately 1,600 such firms, based
on the estimate of 1,460 provided in the
rule, with a 2 to 3 percent annual rate
of growth applied.
FDA received 830 initial serious
adverse event reports in FY 2010. The
number of reports more than doubled to
1,777 in FY 2011. We expect this trend
to continue and, in fact, increase due to
continued industry compliance with
mandatory reporting rules. Based on
this, FDA expects to receive over the
next 3 years an increasing number of
reports per year: We estimate that we
will receive 3,500 in 2012; 7,000 in
2013; and 14,000 in 2014; for an annual
average of 8,166.66 per year, rounded to
8,160. Based on the Agency’s records,
the average number of initial reports per
year on a per firm basis during 2010 and
2011 was 17. Thus, FDA estimates that,
on average over the next 3 years, 480
firms will file 17 initial dietary
supplement serious adverse event
reports, for a total of 8,160 total annual
responses.
FDA estimates that it will take
respondents an average of 2 hours per
report to collect information about a
serious adverse event associated with a
dietary supplement and report the
information to FDA on Form FDA
3500A. Thus, the estimated total annual
hour burden of initial dietary
supplement serious adverse event
reports is 16,320 hours (8,160 responses
× 2 hours) as shown in row 1 of table
1 in this document.
If a respondent that has submitted a
serious adverse event report receives
new information related to the serious
adverse event within 1 year of
submitting the initial report, the
respondent must provide the new
information to FDA in a followup
report. FDA estimates that 25 percent of
serious adverse event reports related to
dietary supplements will have a
followup report submitted, resulting in
approximately 2,040 followup reports
submitted annually (8,160 × 0.25 =
2,040). Assuming that 25 percent of
submitters of initial reports will submit
followup reports (480 × 0.25 = 120) and
the average number of followup reports
per year per firm to be 17, FDA
estimates that, on average over the next
3 years, 120 firms will file 17 followup
reports, for a total of 2,040 total annual
responses. We estimate that each
followup report will require an hour to
assemble and submit, including the time
needed to copy and attach the initial
serious adverse event report as
recommended in the guidance. The
estimated total annual hour burden for
followup reports of new information is
2,040 hours (2,040 responses × 1 hour)
as shown in row 2 of table 1.
The total reporting hour burden is
18,360 hours, which equals the burden
for the mandatory reports (16,320) plus
the burden for the followup new
information (2,040).
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
21 U.S.C. Section
(21 U.S.C. 379aa–1(e)(1))—Dietary supplement adverse
event records ....................................................................
Number of
records per
recordkeeper
1,600
74
Total annual
records
Average
burden per
recordkeeping
118,400
2 0.5
Total hours
59,200
1 There
srobinson on DSK4SPTVN1PROD with NOTICES
2 30
are no capital costs or operating and maintenance costs associated with this collection of information.
minutes.
All 1,600 dietary supplement
manufacturers, packers, or distributors,
are subject to serious adverse event
mandatory recordkeeping, thus FDA
estimates that there are a total of 1,600
recordkeepers. FDA further estimates
that each recordkeeper will keep
VerDate Mar<15>2010
16:12 May 25, 2012
Jkt 226001
approximately 74 records per year, for a
total of 118,400 records. The Agency
estimates that assembling and filing
these records, including any necessary
photocopying, will take approximately
30 minutes, or 0.5 hours, per record.
Therefore, 118,400 records × 0.50 hours
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
= 59,200 total hours. FDA bases its
estimates on its experience with similar
adverse event reporting programs.
Once the documents pertaining to an
adverse event report have been
assembled and filed under the Safety
Reporting Portal, FDA expects the
E:\FR\FM\29MYN1.SGM
29MYN1
31624
Federal Register / Vol. 77, No. 103 / Tuesday, May 29, 2012 / Notices
records retention burden to be minimal,
as the Agency believes most
establishments would normally keep
this kind of record for at least several
years after receiving the report, as a
matter of usual and customary business
practice.
Dated: May 22, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–12878 Filed 5–25–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Dated: May 22, 2012.
Reva Harris,
Acting Director, Division of Policy and
Information Coordination.
Advisory Commission on Childhood
Vaccines; Notice of Meeting
srobinson on DSK4SPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: Advisory Commission on
Childhood Vaccines (ACCV).
Date and Time: June 14, 2012, 8:30 a.m. to
11:45 a.m. EDT.
Place: Parklawn Building (and via audio
conference call), Conference Room 10–65,
5600 Fishers Lane, Rockville, MD 20857.
The ACCV will meet on Thursday, June 14
from 8:30 a.m. to 11:45 a.m. (EDT). The
public can join the meeting via audio
conference call by dialing 1–800–369–3104
on June 14 and providing the following
information:
Leader’s Name: Dr. Geoffrey Evans.
Password: ACCV.
Agenda: The agenda items for the June
meeting will include, but are not limited to:
updates from the Division of Vaccine Injury
Compensation (DVIC), Department of Justice
(DOJ), National Vaccine Program Office
(NVPO), Immunization Safety Office (Centers
for Disease Control and Prevention), National
Institute of Allergy and Infectious Diseases
(National Institutes of Health) and Center for
Biologics, Evaluation and Research (Food
and Drug Administration). A draft agenda
and additional meeting materials will be
posted on the ACCV Web site (https://
www.hrsa.gov/vaccinecompensation/
accv.htm) prior to the meeting. Agenda items
are subject to change as priorities dictate.
Public Comment: Persons interested in
attending the meeting in person or providing
an oral presentation should submit a written
request, along with a copy of their
presentation to: Annie Herzog, DVIC,
Healthcare Systems Bureau (HSB), Health
Resources and Services Administration
(HRSA), Room 11C–26, 5600 Fishers Lane,
Rockville, Maryland 20857 or email:
aherzog@hrsa.gov. Requests should contain
the name, address, telephone number, email
address, and any business or professional
affiliation of the person desiring to make an
oral presentation. Groups having similar
interests are requested to combine their
VerDate Mar<15>2010
16:12 May 25, 2012
Jkt 226001
comments and present them through a single
representative. The allocation of time may be
adjusted to accommodate the level of
expressed interest. DVIC will notify each
presenter of their assigned presentation time
by email, mail, or telephone. Persons who do
not file an advance request for a presentation,
but desire to make an oral statement, may
announce it at the time of the public
comment period. Public participation and
ability to comment will be limited to space
and time as it permits.
For Further Information Contact: Anyone
requiring information regarding the ACCV
should contact: Annie Herzog, DVIC, HSB,
HRSA, Room 11C–26, 5600 Fishers Lane,
Rockville, MD 20857; telephone (301) 443–
6593; email: aherzog@hrsa.gov.
[FR Doc. 2012–12849 Filed 5–25–12; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; 2012–10 K and R13
Review Teleconference.
Date: June 25, 2012.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Rm. 951, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Ruixia Zhou, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Democracy Two Building, Suite
957, Bethesda, MD 20892, 301–496–4773,
zhour@mail.nih.gov.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Dated: May 21, 2012.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–12866 Filed 5–25–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Recombinant DNA
Advisory Committee.
Date: June 19, 2012.
Time: 9:00 a.m. to 3:30 p.m.
Agenda: The NIH Recombinant DNA
Advisory Committee (RAC) will discuss
selected human gene transfer protocols.
Please view the meeting agenda at https://
oba.od.nih.gov/rdna_rac/rac_meetings.html
for more information.
Place: National Institutes of Health,
Building 31C, 9000 Rockville Pike, 6th Floor
Conference Room, Rockville, MD 20892.
Contact Person: Chezelle George, Office of
Biotechnology Activities, Office of Science
Policy/OD, National Institutes of Health,
6705 Rockledge Drive, Room 750, Bethesda,
MD 20892, 301–496–9838,
georgec@od.nih.gov.
OBA will again offer those members of the
public viewing the meeting via webcast (see
OBA Meetings Page available at https://
oba.od.nih.gov/rdna_rac/rac_meetings.html)
the opportunity to submit comments during
the public comment periods. Individuals
wishing to submit comments should use the
comment form, which will accommodate
comments up to 1500 characters, and will be
available on the OBA Web site during the
meeting (see OBA Meetings Page). Please
limit your comments to a statement that can
be read in one to two minutes. Please include
your name and affiliation with your
comment. Only comments submitted through
the OBA Web site will be read.
OBA will read comments into the record
during the public comment periods as stated
on the agenda. It is not unusual for the
meeting to run ahead or behind schedule due
to changes in the time needed to review a
protocol. It is advisable to monitor the
webcast to determine when public comments
will be read. Each public comment period
follows a specific discussion item. OBA will
E:\FR\FM\29MYN1.SGM
29MYN1
Agencies
[Federal Register Volume 77, Number 103 (Tuesday, May 29, 2012)]
[Notices]
[Pages 31622-31624]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12878]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0274]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Adverse Event
Reporting and Recordkeeping for Dietary Supplements as Required by the
Dietary Supplement and Nonprescription Drug Consumer Protection Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by June
28, 2012.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0428.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400T,
Rockville, MD 20850, 301-796-5733, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Adverse Event Reporting and Recordkeeping for Dietary Supplements as
Required by the Dietary Supplement and Nonprescription Drug Consumer
Protection Act--21 U.S.C. 379aa-1(b)(1) (OMB Control Number 0910-
0635)--Extension
The Dietary Supplement and Nonprescription Drug Consumer Protection
Act (DSNDCPA) (Pub. L. 109-462, 120 Stat. 3469) amends the Federal
Food, Drug, and Cosmetic Act (the FD&C Act) with respect to serious
adverse event reporting and recordkeeping for dietary supplements and
nonprescription drugs marketed without an approved application. Section
761(b)(1) of the FD&C Act (21 U.S.C. 379aa-1(b)(1)) requires the
manufacturer, packer, or distributor whose name (under section
403(e)(1) of the FD&C Act (21 U.S.C. 343(e)(1))) appears on the label
of a dietary supplement marketed in the United States to submit to FDA
all serious adverse event reports associated with the use of a dietary
supplement, accompanied by a copy of the product label. The
manufacturer, packer, or distributor of a dietary supplement is
required by the DSNDCPA to use the MedWatch form (FDA 3500A) when
submitting a serious adverse event report to FDA. In addition, under
section 761(c)(2) of the FD&C Act, the submitter of the serious adverse
event report (referred to in the statute as the ``responsible person'')
is required to submit to FDA a followup report of any related new
medical information the responsible person receives within 1 year of
the initial report.
Section 761(e)(1) of the FD&C Act (21 U.S.C. 379aa-1(e)(1))
requires that responsible persons maintain records related to the
dietary supplement adverse event reports they receive, whether or not
the adverse event is serious. Under the statute, the records must be
retained for a period of 6 years.
As required by section 3(d)(3) of the DSNDCPA, FDA issued guidance
to describe the minimum data elements for serious adverse event reports
for dietary supplements. In the Federal Register of July 14, 2009 (74
FR 34024), FDA announced the availability of guidance entitled
``Guidance for Industry: Questions and Answers Regarding Adverse Event
Reporting and Recordkeeping for Dietary Supplements as Required by the
Dietary Supplement and Nonprescription Drug Consumer Protection Act.''
The guidance discusses how, when, and where to submit serious adverse
event reports for dietary supplements and followup reports. The
guidance also provides FDA's recommendation on records maintenance and
access for serious and non-serious adverse event reports and related
documents.
The guidance recommends that the responsible person document the
attempts to obtain the minimum data elements for a serious adverse
event report. Along with these records, the guidance recommends that
the responsible person keep the following other records: (1)
Communications between the responsible person and the initial reporter
of the adverse event and
[[Page 31623]]
between the responsible person and any other person(s) who provided
information about the adverse event, (2) the responsible person's
serious adverse event report to FDA with attachments, (3) any new
information about the adverse event received by the responsible person,
and (4) any reports to FDA of new information related to the serious
adverse event report.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
21 U.S.C. Section Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
21 U.S.C. 379aa-1(b)(1)--Serious 480 17 8,160 2 16,320
adverse event reports for
dietary supplements............
21 U.S.C. 379aa-1(c)(2)-- 120 17 2,040 1 2,040
Followup reports of new medical
information....................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 18,360
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
This estimate is based on FDA's experience with similar adverse
event reporting programs and the number of serious adverse event
reports and followup reports received in the past 2 years. All dietary
supplement manufacturers, packers, or distributors are subject to
serious adverse event mandatory reporting. In 2007, we estimated in the
final rule entitled ``Current Good Manufacturing Practice in
Manufacturing, Packaging, Labeling, or Holding Operations for Dietary
Supplements'' (72 FR 34752, June 25, 2007) that there were 1,460 such
firms. FDA estimates that, in 2012, there are approximately 1,600 such
firms, based on the estimate of 1,460 provided in the rule, with a 2 to
3 percent annual rate of growth applied.
FDA received 830 initial serious adverse event reports in FY 2010.
The number of reports more than doubled to 1,777 in FY 2011. We expect
this trend to continue and, in fact, increase due to continued industry
compliance with mandatory reporting rules. Based on this, FDA expects
to receive over the next 3 years an increasing number of reports per
year: We estimate that we will receive 3,500 in 2012; 7,000 in 2013;
and 14,000 in 2014; for an annual average of 8,166.66 per year, rounded
to 8,160. Based on the Agency's records, the average number of initial
reports per year on a per firm basis during 2010 and 2011 was 17. Thus,
FDA estimates that, on average over the next 3 years, 480 firms will
file 17 initial dietary supplement serious adverse event reports, for a
total of 8,160 total annual responses.
FDA estimates that it will take respondents an average of 2 hours
per report to collect information about a serious adverse event
associated with a dietary supplement and report the information to FDA
on Form FDA 3500A. Thus, the estimated total annual hour burden of
initial dietary supplement serious adverse event reports is 16,320
hours (8,160 responses x 2 hours) as shown in row 1 of table 1 in this
document.
If a respondent that has submitted a serious adverse event report
receives new information related to the serious adverse event within 1
year of submitting the initial report, the respondent must provide the
new information to FDA in a followup report. FDA estimates that 25
percent of serious adverse event reports related to dietary supplements
will have a followup report submitted, resulting in approximately 2,040
followup reports submitted annually (8,160 x 0.25 = 2,040). Assuming
that 25 percent of submitters of initial reports will submit followup
reports (480 x 0.25 = 120) and the average number of followup reports
per year per firm to be 17, FDA estimates that, on average over the
next 3 years, 120 firms will file 17 followup reports, for a total of
2,040 total annual responses. We estimate that each followup report
will require an hour to assemble and submit, including the time needed
to copy and attach the initial serious adverse event report as
recommended in the guidance. The estimated total annual hour burden for
followup reports of new information is 2,040 hours (2,040 responses x 1
hour) as shown in row 2 of table 1.
The total reporting hour burden is 18,360 hours, which equals the
burden for the mandatory reports (16,320) plus the burden for the
followup new information (2,040).
Table 2--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
21 U.S.C. Section Number of records per Total annual per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
(21 U.S.C. 379aa-1(e)(1))-- 1,600 74 118,400 \2\ 0.5 59,200
Dietary supplement adverse
event records..................
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ 30 minutes.
All 1,600 dietary supplement manufacturers, packers, or
distributors, are subject to serious adverse event mandatory
recordkeeping, thus FDA estimates that there are a total of 1,600
recordkeepers. FDA further estimates that each recordkeeper will keep
approximately 74 records per year, for a total of 118,400 records. The
Agency estimates that assembling and filing these records, including
any necessary photocopying, will take approximately 30 minutes, or 0.5
hours, per record. Therefore, 118,400 records x 0.50 hours = 59,200
total hours. FDA bases its estimates on its experience with similar
adverse event reporting programs.
Once the documents pertaining to an adverse event report have been
assembled and filed under the Safety Reporting Portal, FDA expects the
[[Page 31624]]
records retention burden to be minimal, as the Agency believes most
establishments would normally keep this kind of record for at least
several years after receiving the report, as a matter of usual and
customary business practice.
Dated: May 22, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-12878 Filed 5-25-12; 8:45 am]
BILLING CODE 4160-01-P